Biomarkers, C-reactive proteins and statins in acute coronary syndromes.
Atherosclerosis is now widely accepted as an active process involving a pathological vascular triad of vascular cellular activation, inflammation, and thrombosis. Several biomarkers show promise for risk prediction in high risk patients in large scale studies. Some are modified by statin therapy and may be targets for future therapeutic drug development whereas others identify high risk groups that benefit from specific treatments such as intensive statin therapy. Further understanding the role of different biomarkers will help better understand the pathophysiology of ACS as well as provide personalized medical care.
Ray
Kausik K
KK
Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK.
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D023201:CD40 Ligand / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood; D019798:Neopterin / Q000097:blood
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020097:Natriuretic Peptide, Brain; D018799:Intercellular Adhesion Molecule-1; D023201:CD40 Ligand; D019798:Neopterin; D002097:C-Reactive Protein; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase